《公司业绩》人保集团(01339.HK)全年纯利200.36亿人币跌9.5% 末期息增至12分
中国人民保险集团(01339.HK)公布截至去年12月底止全年业绩,总保费收入5,636.08亿元人民币(下同),按年升1.5%。纯利200.36亿元,按年跌9.5%;每股盈利0.45元。派末期息12分,上年同期派11.6分。计及中期股息每股3.6分,全年派息15.6分。
期内人保财险实现总保费收入4,331.87亿元,按年大致持平,综合成本率98.9%,综合偿付能力充足率289%;人保健康实现总保费收入322.57亿元,增长43.9%;人保寿险总保费收入961.9亿元,按年跌2%。人身险板块实现新业务价值61.32亿元,按年增长9.7%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.